- BioCina partners with EnGeneIC to deliver GMP manufacturing for EDV™ nanocell-based cancer therapeutics.
- The project includes technology transfer, process scale-up, and preparation for clinical and commercial production.
BioCina Pty Ltd., a global biologics Contract Development and Manufacturing Organization (CDMO), has announced a partnership with drug developer EnGeneIC Pty Ltd. This collaboration focuses on the technology transfer, process scale-up, and GMP batch manufacture of EnGeneIC’s proprietary ‘EnGeneIC Dream Vector’ (EDV™) nanocells.
EnGeneIC is working to advance cancer treatment with its Antibody-Nanocell Drug Conjugates (ANDCs) based on the EDV™ platform. The platform utilises antibody-targeted, non-living nanocells to deliver chemotherapy directly into tumour cells, aiming to reduce toxicity and target drug-resistant cancers. BioCina will provide end-to-end services to prepare the technology for clinical trials and commercial manufacturing.
Mark W. Womack, CEO of BioCina, expressed pride in the collaboration, stating, “I’m so very proud for BioCina to be entrusted to advance EnGeneIC’s transformative therapeutic, which has the potential to make a profound impact on previously untreatable cancers.”
Dr. Himanshu Brahmbhatt, Co-Founder and CEO of EnGeneIC, emphasised the importance of this partnership, noting that BioCina’s commitment to cancer patients gives them confidence in the success of the project.
Overview of outsourcing trends 
